These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

703 related items for PubMed ID: 23621346

  • 1. Fragment-based lead discovery on G-protein-coupled receptors.
    Visegrády A, Keserű GM.
    Expert Opin Drug Discov; 2013 Jul; 8(7):811-20. PubMed ID: 23621346
    [Abstract] [Full Text] [Related]

  • 2. Structure-based and fragment-based GPCR drug discovery.
    Andrews SP, Brown GA, Christopher JA.
    ChemMedChem; 2014 Feb; 9(2):256-75. PubMed ID: 24353016
    [Abstract] [Full Text] [Related]

  • 3. From purified GPCRs to drug discovery: the promise of protein-based methodologies.
    Alkhalfioui F, Magnin T, Wagner R.
    Curr Opin Pharmacol; 2009 Oct; 9(5):629-35. PubMed ID: 19443270
    [Abstract] [Full Text] [Related]

  • 4. Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists.
    Hagiwara Y, Ohno K, Kamohara M, Takasaki J, Watanabe T, Fukunishi Y, Nakamura H, Orita M.
    Expert Opin Drug Discov; 2013 Aug; 8(8):951-64. PubMed ID: 23682717
    [Abstract] [Full Text] [Related]

  • 5. Emerging Approaches to GPCR Ligand Screening for Drug Discovery.
    Kumari P, Ghosh E, Shukla AK.
    Trends Mol Med; 2015 Nov; 21(11):687-701. PubMed ID: 26481827
    [Abstract] [Full Text] [Related]

  • 6. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R, Wolff M, Tautermann CS, Bieler M.
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [Abstract] [Full Text] [Related]

  • 7. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C, Ottl J.
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [Abstract] [Full Text] [Related]

  • 8. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.
    Huang B, Kang D, Zhan P, Liu X.
    Expert Opin Drug Discov; 2015 Dec; 10(12):1271-81. PubMed ID: 26372893
    [Abstract] [Full Text] [Related]

  • 9. In silico fragment-based drug design.
    Konteatis ZD.
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [Abstract] [Full Text] [Related]

  • 10. Ligand and decoy sets for docking to G protein-coupled receptors.
    Gatica EA, Cavasotto CN.
    J Chem Inf Model; 2012 Jan 23; 52(1):1-6. PubMed ID: 22168315
    [Abstract] [Full Text] [Related]

  • 11. From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands.
    Kooistra AJ, Roumen L, Leurs R, de Esch IJ, de Graaf C.
    Methods Enzymol; 2013 Jan 23; 522():279-336. PubMed ID: 23374191
    [Abstract] [Full Text] [Related]

  • 12. PREDICT modeling and in-silico screening for G-protein coupled receptors.
    Shacham S, Marantz Y, Bar-Haim S, Kalid O, Warshaviak D, Avisar N, Inbal B, Heifetz A, Fichman M, Topf M, Naor Z, Noiman S, Becker OM.
    Proteins; 2004 Oct 01; 57(1):51-86. PubMed ID: 15326594
    [Abstract] [Full Text] [Related]

  • 13. Ligand Discovery for a Peptide-Binding GPCR by Structure-Based Screening of Fragment- and Lead-Like Chemical Libraries.
    Ranganathan A, Heine P, Rudling A, Plückthun A, Kummer L, Carlsson J.
    ACS Chem Biol; 2017 Mar 17; 12(3):735-745. PubMed ID: 28032980
    [Abstract] [Full Text] [Related]

  • 14. Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity.
    Chen D, Errey JC, Heitman LH, Marshall FH, Ijzerman AP, Siegal G.
    ACS Chem Biol; 2012 Dec 21; 7(12):2064-73. PubMed ID: 23013674
    [Abstract] [Full Text] [Related]

  • 15. Recent progress in fragment-based lead discovery.
    Schulz MN, Hubbard RE.
    Curr Opin Pharmacol; 2009 Oct 21; 9(5):615-21. PubMed ID: 19477685
    [Abstract] [Full Text] [Related]

  • 16. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T.
    Methods Enzymol; 2011 Oct 21; 493():469-85. PubMed ID: 21371602
    [Abstract] [Full Text] [Related]

  • 17. The use of GPCR structures in drug design.
    Congreve M, Langmead C, Marshall FH.
    Adv Pharmacol; 2011 Oct 21; 62():1-36. PubMed ID: 21907905
    [Abstract] [Full Text] [Related]

  • 18. Modeling small molecule-compound binding to G-protein-coupled receptors.
    Vaidehi N, Pease JE, Horuk R.
    Methods Enzymol; 2009 Oct 21; 460():263-88. PubMed ID: 19446730
    [Abstract] [Full Text] [Related]

  • 19. G protein-coupled receptor microarrays for drug discovery.
    Fang Y, Lahiri J, Picard L.
    Drug Discov Today; 2004 Dec 15; 9(24 Suppl):S61-7. PubMed ID: 23573662
    [Abstract] [Full Text] [Related]

  • 20. Characterizing common substructures of ligands for GPCR protein subfamilies.
    Erguner B, Hattori M, Goto S, Kanehisa M.
    Genome Inform; 2010 Dec 15; 24():31-41. PubMed ID: 22081587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.